Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer

Kurume Medical Journal

Volumn 49, Issue 1-2, 2002, Pages 27-33

  Aoyama, Yuko ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Estrogen receptor negative breast cancer; G2 arrest; N (4 hydroxyphenyl)retinamide; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; FENRETINIDE; GANGLIOSIDE GM3; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; THIN LAYER CHROMATOGRAPHY;

EID: 0036367059     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.49.27     Document Type: Article

References (30)

1. Early breast cancer trialists' collaborative group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy; 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:1-15.
2. Abe O. The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer: meta-analysis of the first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC). Breast Cancer 1994; 1:1-9.
3. Kuerer HM, Buzdar AU, and Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 2001; 77:139-147.
4. Klijn JG, Blarney RW, Boccardo F, Tominaga T, Duchateau L et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: meta-analysis of four randomized trials. J Clin Oncol 2001; 19:343-353.
5. Gould MN. Prevention and therapy of mammary cancer by monoterpenes. J Cell Biochem 1995 (Suppl); 22:139-144.
6. Frey RS, Li J, and Singletary KW. Effect of genistein on cell proliferation and cell cycle arrest in nonnneoplastic human mammary epithelial cells: involvement of Cdc2, p21(waf/cip1) p27(kip1), and Cdc25C expression. Biochem Pharmacol 2001; 61:979-989.
7. Bischoff ED, Heyman RA, and Lamph WW. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 1999; 91:2118.
8. El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 2000; 60:4412-4418.
9. Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS et al. Blockade of growth factor receptors inductal carcinoma in situ inhibits epithelialproliferation. Br J Surg 2001; 88:412-418.
10. Harris RE, Alshafie GA, Abou-Issa H, and Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60:2101-2103.
11. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ et al. N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979; 39:1339-1346.
12. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F et al. Randamized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91:1847-1856.
13. Camerini T, Mariani L, DePalo G, Marubini E, Di Mauro MG et al. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2001; 19:1664-1670.
14. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Torrisi R, Manetti L et al. Chemoprevention of breast cancer: The Italian experience. J Cell Biochem 2000; 77:84-96.
15. Panigone S, Debernardi S, Taya Y, Fontanella E, Airoldi R et al. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide. Oncogene 2000 19: 4035-4041.
16. Ciolino HP, Wang TT, and Sathyamoorthy N. Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide. Br J Cancer 2000; 83:333-337.
17. Mariotti A, Marcora E, Bunone G, Costa A, Veronesi U et al. N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 1994; 86:1245-1247.
18. Supino R, Crosti M, Clerici M, Warlters A, Cleris L et al. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 1996; 65:491-497.
19. Kalemkerian GP, Slusher R, Ramalingam S, Gadgeel S, and Mabry M. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst 1995; 87:1674-1680.
20. McCormick DL, Mehta RG, Thompson CA, Dinger N, Caldwell JA et al. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy. Cancer Res 1982; 42:508-512.
21. Coradini D, Biffi A, Pellizzaro C, Pirronello E, and Fronzo G. Combined effect of tamoxifen or interferon-beta and 4-hydroxyphenylretinamide in the growth of breast cancer cell lines. Tumour Biol 1997; 18:22-29.
22. Lawrence JA, Adamson PC, Caruso R, Chow C, Kleiner D et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol 2001; 19:2754-2763.
23. Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C et al. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl)retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 2000; 18:275-283.
24. Marquina G, Waki H, Fernandez LE, Kon K, Carr A et al. Gangliosides expressed in human breast cancer. Cancer Res 1996; 56:5165-5171.
25. Nohara K, Wang F, and Spiegel S. Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines. Breast Cancer Res Treat 1998; 48:149-157.
26. Rossi F, Gornati R, Rizzo AM, Venturini L, Bernardini G et al. Glycolipid glycosyltransferase activities during early development of Xenopus: effect of retinoic acid. Cell Biol Int 1999; 23:91-95.
27. Chen C, Fenderson BA, Andrews PW, and Hakomori S. Glycolipid glycosyltransferases in human embryonal carcinoma cells during retinoic acid induced differentiation. Biochemistry 1989; 28:2229-2238.
28. Dipietrantonio A, Hsieh TC, and Wu JM. Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Biochem Biophys Res Commun 1996; 224:837-842.
29. Panigone S, Debernardi S, Taya Y, Fontanella E, Airoldi R et al. pRb and Cdk regulation by N-(4-hydroxyphenyl) retinamide. Oncogene 2000; 19:4035-4041.
30. Aydiner A, Ridvanogullari M, Anil D, Topuz E, Nurten R et al. Combined effects of epirubicin and tamoxifen on the cell-cycle phases in estrogen-receptor-negative Ehrlich ascites tumor cells. J Cancer Res Clin Oncol 1997; 123:113-117.